Avalon GloboCare Corp. (NASDAQ:CHGA) Short Interest Update

Avalon GloboCare Corp. (NASDAQ:CHGA) was the recipient of a significant decline in short interest during the month of August. As of August 31st, there was short interest totaling 68,808 shares, a decline of 69.7% from the August 15th total of 226,852 shares. Approximately 9.6% of the shares of the company are sold short. Based on an average daily trading volume, of 723,976 shares, the days-to-cover ratio is presently 0.1 days.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Avalon GloboCare from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, August 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Avalon GloboCare currently has a consensus rating of “Sell”.

Avalon GloboCare Trading Down 4.5%

Avalon GloboCare stock traded down $0.10 during midday trading on Monday, reaching $2.13. The company’s stock had a trading volume of 33,257 shares, compared to its average volume of 206,798. The business has a 50-day moving average price of $4.76 and a 200-day moving average price of $7.90. The stock has a market cap of $2.02 million, a PE ratio of -0.15 and a beta of -0.05. Avalon GloboCare has a 52 week low of $2.01 and a 52 week high of $57.40.

Avalon GloboCare (NASDAQ:CHGA) last issued its earnings results on Friday, August 14th. The company reported ($2.80) earnings per share for the quarter.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.